Muscarinic acetylcholine receptor M3
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Muscarinic acetylcholine receptor M3 as ChEMBL target CHEMBL5105, mapped to UniProt Q9ERZ3. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Muscarinic acetylcholine receptor M3 matters
Muscarinic acetylcholine receptor M3 is reviewed as Muscarinic acetylcholine receptor M3 (UniProt Q9ERZ3); the current evidence base includes 2 approved drugs, 42 compounds, and 8 assays, with lead potency reaching pChEMBL 6.0.
Muscarinic acetylcholine receptor M3 Sequence length is 589 aa.
Review this target as Muscarinic acetylcholine receptor M3, mapped to UniProt Q9ERZ3. Sequence length is 589 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 2 approved drugs, 42 compounds, and 8 assays for this target. The dominant activity type is EC50. CHEMBL277014 is the current potency anchor at pChEMBL 6.0.
Use CHEMBL277014 as the tractability anchor when discussing potency (pChEMBL 6.0).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Muscarinic acetylcholine receptor M3 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt Q9ERZ3, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL277014
|
6.0 | EC50 | — |
|
|
No preferred name
CHEMBL12378
|
5.5 | EC50 | — |
|
|
No preferred name
CHEMBL281411
|
5.2 | EC50 | — |
|
|
No preferred name
CHEMBL14
|
5.0 | EC50 | Approved |
|
|
No preferred name
CHEMBL20835
|
5.0 | EC50 | Clinical |